MATEON THERAPEUTICS, INC. (NASDAQ:MATN) Files An 8-K Other Events
Item8.01
| Other Events. |
On December6, 2016, Mateon Therapeutics, Inc. (Mateon) issued a
press release announcing the presentation of OXi4503 acute
myeloid leukemia (AML) study data at the 58th Annual Meeting of the American
Society of Hematology. OXi4503 is one of Mateons two vascular
disrupting agents (VDAs) currently in clinical development.
A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.
| Item9.01 | Financial Statements and Exhibits. |
The following exhibit is furnished with this report:
|
Exhibit Number |
Description |
|
| 99.1 | Press Release dated December 6, 2016. |
About MATEON THERAPEUTICS, INC. (NASDAQ:MATN)
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA. MATEON THERAPEUTICS, INC. (NASDAQ:MATN) Recent Trading Information
MATEON THERAPEUTICS, INC. (NASDAQ:MATN) closed its last trading session down -0.013 at 0.378 with 450,805 shares trading hands.